Bexagliflozin(Bexagliflozin) - 药物靶点：SGLT2_在研适应症：2型糖尿病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Bexagliflozin (USAN)、Bexagliflozin L-proline、EGT-0001442

+ [5]

靶点

SGLT2

作用机制

SGLT2抑制剂(钠-葡萄糖协同转运蛋白-2抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

恒翼生物医药（上海）股份有限公司Piramal Healthcare UK Ltd.

Theracos, Inc.

非在研机构

Theracos Holdings Ltd.

最高研发阶段批准上市

首次获批日期

美国 (2023-01-20),

2型糖尿病

最高研发阶段(中国)申请上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C24H29ClO7

InChIKeyBTCRKOKVYTVOLU-SJSRKZJXSA-N

CAS号1118567-05-7

关联

26

项与 Bexagliflozin 相关的临床试验

NCT05612594

/ Recruiting临床4期IIT

Adipose Dysfunction, Imaging, Physiology, and Outcomes With SGLT2i's for Sleep Apnea: The ADIPOSA Study

The goal of this clinical trial is to test if bexagliflozin lowers the sleep apnea severity in adults who are overweight or obese with moderate to severe obstructive sleep apnea (OSA) compared with a placebo (look-alike substance that contains no active drug).
The main question it aims to answer is:
* If SGLT2i will reduce anatomic and physiologic traits, clinical measures of OSA and sleep deficiency in participants
* If improvement in clinical measures are because of improvement in the anatomic and physiologic traits.
Participants will be placed on either drug or placebo and get routine normal care for 6 months. At the start and end of the study, participants will undergo different clinical measurements to see if the drug makes the sleep apnea better.

开始日期2024-03-27

申办/合作机构

Yale University

[+1]

NCT05369078

/ Unknown status临床1期

Phase I Clinical Study to Evaluate the Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy Subjects

The purpose of this study was to investigate Safety, tolerability and pharmacokinetics in Chinese healthy subjects.

开始日期2021-12-01

申办/合作机构

恒翼生物医药（上海）股份有限公司

CTR20212958

/ Completed临床1期

评价THR-1442在中国健康受试者中安全性、耐受性、药代动力学特征的开放、单次和多次给药的I期临床研究

主要目的评价THR-1442在健康受试者中的安全性和耐受性；次要目的建立THR-1442健康受试者中的药代动力学特征；根据THR-1442在美国人群和日本人群的健康受试者药代动力学数据，进行间接比较在中国人群的药代动力学特征。

开始日期2021-11-30

申办/合作机构

恒翼生物医药（上海）股份有限公司

[+2]

100 项与 Bexagliflozin 相关的临床结果

登录后查看更多信息

100 项与 Bexagliflozin 相关的转化医学

登录后查看更多信息

100 项与 Bexagliflozin 相关的专利（医药）

登录后查看更多信息

22

项与 Bexagliflozin 相关的文献（医药）

Review

2024-04-01·Journal of diabetes

Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24‐week, randomized, double‐blind, active‐controlled, phase 3 trial

Article

作者: Chen, Jinyu ; Zhang, Wei ; Thurber, Tara K ; Bian, Fang ; Cheng, Zhifeng ; Xie, Lingding ; Sun, Wenli ; Zhu, Qian ; Lock, J Paul ; Liu, Dexue ; Han, Jie ; Xu, Chunrong ; Zhang, Bo ; Li, Qingju ; Liu, Jie

Abstract:

Background:

Bexagliflozin and dapagliflozin are sodium‐glucose cotransporter‐2 (SGLT2) inhibitors. No direct comparison of SGLT2 inhibitors in a randomized controlled trial has been reported to date.

Methods:

This was a multicenter, randomized, double‐blind, active‐controlled trial comparing bexagliflozin to dapagliflozin for the treatment of type 2 diabetes mellitus in adults with disease inadequately controlled by metformin. Subjects (n = 406) were randomized to receive bexagliflozin (20 mg) or dapagliflozin (10 mg) plus metformin. The primary endpoint was noninferiority of bexagliflozin to dapagliflozin for the change in glycated hemoglobin (HbA1c) from baseline to week 24. Secondary endpoints included intergroup differences in fasting plasma glucose (FPG), 2‐h‐postprandial glucose (PPG), body weight, and systolic blood pressure (SBP) from baseline to week 24. The trial also evaluated the safety profiles.

Results:

The model‐adjusted mean change from baseline to week 24 HbA1c was −1.08% for bexagliflozin and −1.10% for dapagliflozin. The intergroup difference of 0.03% (95% confidence interval [CI] −0.14% to 0.19%) was below the prespecified margin of 0.4%, confirming the noninferiority of bexagliflozin. The changes from baseline in FPG, PPG, body weight, and SBP were −1.95 mmol/L, −3.24 mmol/L, −2.52 kg, and −6.4 mm Hg in the bexagliflozin arm and −1.87 mmol/L, −3.07 mmol/L, −2.22 kg, and −6.3 mm Hg in the dapagliflozin arm. Adverse events were experienced in 62.6% and 65.0% and serious adverse events affected 4.4% and 3.5% of subjects in the bexagliflozin and dapagliflozin arm, respectively.

Conclusions:

Bexagliflozin showed nearly identical effects and a similar safety profile to dapagliflozin when used in Chinese patients on metformin.image

2024-03-01·Diabetes, obesity & metabolism

Meta‐analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin

Article

作者: Freeman, Mason W. ; Zhou, Wenjiong ; Halvorsen, Yuan‐Di C. ; Lock, J. Paul ; Zhu, Fang ; Solomon, Scott D. ; Skali, Hicham ; Massaro, Joseph M. ; Lewis, Eldrin F. ; McMurray, John J. V.

Abstract:

Aim:

To explore the risk of major adverse cardiovascular events (MACE) associated with exposure to bexagliflozin.

Methods:

The analysis included 4090 participants with type 2 diabetes (T2D) enrolled in nine phase 2 and 3 double‐blind randomized controlled trials. All potential MACE were adjudicated by a blinded committee. The primary endpoint for the meta‐analysis was the hazard ratio (HR) for the time to first occurrence of non‐fatal stroke, non‐fatal myocardial infarction (MI), cardiovascular (CV) death or hospitalization for unstable angina (MACE+), tested for non‐inferiority to a ratio of 1.8. The secondary endpoints were time to first occurrence of (i) non‐fatal stroke, non‐fatal MI or CV death (MACE), tested for non‐inferiority to a ratio of 1.3; and (ii) CV death or hospitalization for heart failure, tested for superiority.

Results:

The HR for the primary endpoint of MACE+ was 0.80 (95% confidence interval [CI] 0.58, 1.09), which fulfilled the non‐inferiority objective with a P value of less than 0.0001. Non‐inferiority for the first key secondary endpoint of MACE was also shown (HR = 0.82; 95% CI 0.59, 1.13; P = 0.0023). Superiority for time to CV death or first hospitalization for heart failure was not shown.

Conclusions:

Bexagliflozin did not increase the risk of MACE in participants with T2D when compared with placebo or active control. Both the preapproval and postapproval thresholds for CV safety were met and bexagliflozin has been approved by the US Food and Drug Administration.

42

项与 Bexagliflozin 相关的新闻（医药）

2024-12-12

·Business Wire

A Study in the New Issue of JAMA Network Open Reveals Income-Related Disparities in Type 2 Diabetes Outcomes Despite Equivalent Access to Healthcare

MARLBOROUGH, Mass.--( BUSINESS WIRE )--A new study published in JAMA Network Open titled “ Income-Related Disparities in Mortality Among Young Adults With Type 2 Diabetes ” underscores the need for addressing disparities in care and improving access to important therapies for type 2 diabetes. This study further underscores recent data compiled by the American Diabetes Association which states that diabetes is the most expensive chronic condition in the United States, and millions of Americans struggle to afford effective treatment of their type 2 diabetes and associated complications. Seeking to address this critical health issue, BRENZAVVY ® (bexagliflozin) is a safe, effective and affordable option for adults with type 2 diabetes. In the United States, BRENZAVVY is sold at around $50 per month through a network of online and independent pharmacies. BRENZAVVY's low price point makes sodium-glucose cotransporter 2 (SGLT2) inhibitor therapy a more affordable option for uninsured, underinsured, and Medicare patients. This increased affordability can help ensure that patients can initiate and maintain a safe and effective therapy, improving their ability to manage their type 2 diabetes. Adults with type 2 diabetes can easily determine if BRENZAVVY is right for them by visiting www.brenzavvydirect.com and speaking to a doctor quickly and affordably. For healthcare providers, BRENZAVVY can easily be prescribed without insurance plan headaches, such as prior authorizations or step therapy hurdles, that the SGLT2 inhibitor class traditionally faces. “ The findings of this study reinforce that many adults living with type 2 diabetes simply cannot afford to start and stay on their therapy ,” said the TheracosBio CEO, Brian Connelly. “ With BRENZAVVY, TheracosBio is fulfilling our mission to address financial barriers to care. By unlocking wider access to an important class of therapy, more and more people with type 2 diabetes have better access to a safe, affordable and effective treatment option,” Mr. Connelly added. BRENZAVVY is available as 20 mg oral tablets to be taken once daily, in the morning, with or without food. Phase 3 clinical studies have shown BRENZAVVY significantly reduces hemoglobin A1c and fasting blood sugar after 24 weeks, either as a monotherapy, in combination with metformin, or as an add-on to standard-of-care treatment consisting of a variety of regimens, including metformin, sulfonylureas, insulin, DPP4 inhibitors or combinations of these agents. Although BRENZAVVY is not approved for weight loss or blood pressure reduction, modest decreases in both weight and blood pressure have been observed in the clinical program. To learn more about BRENZAVVY , please visit https://www.brenzavvy.com . To learn more about TheracosBio, please visit https://theracosbio.com . BRENZAVVY Important Safety Information BRENZAVVY ® (bexagliflozin) is a prescription medicine used along with diet and exercise to improve blood sugar in adults with type 2 diabetes. BRENZAVVY is not recommended to decrease blood sugar in people with type 1 diabetes. Do not take BRENZAVVY if you are allergic to bexagliflozin or any of the ingredients in BRENZAVVY. BRENZAVVY can cause serious side effects including diabetic ketoacidosis that may be fatal. Signs and symptoms of ketoacidosis include nausea, vomiting, stomach pains, tiredness, trouble breathing, and ketones in urine or blood. Ketoacidosis can happen even if your blood sugar is less than 250 mg/dL. BRENZAVVY may increase the risk of lower limb amputations. Call your doctor if you notice signs or symptoms. Amputations mainly involve removal of the toe or part of the foot, however, amputations involving the leg, below and above the knee, have also occurred. Some people had more than one amputation. BRENZAVVY may cause dehydration, urinary tract or genital yeast infections, and low blood sugar. Symptoms of dehydration include feeling dizzy, faint, lightheaded, or weak upon standing. Yeast infections can occur in women and men. Signs of low blood sugar may include headache, confusion, drowsiness, dizziness, sweating, irritability, hunger, shaking, fast heartbeat, or weakness. A rare life-threatening bacterial infection in the skin of the perineum could occur. Stop taking BRENZAVVY and call your doctor right away if you have symptoms of this infection The perineum is the area between the anus and genitals. Symptoms of this infection include fever, weakness and pain tenderness, redness, or swelling of the genital area. The most common side effects of BRENZAVVY are vaginal yeast infections, urinary tract infections, and changes in urination, including an urgent need to urinate more often, in large amounts, and at night. For additional important safety information about BRENZAVVY, visit www.brenzavvy.com . About TheracosBio TheracosBio was founded in 2000 and develops affordably priced novel therapeutics for diseases with significant societal impact. The mission of TheracosBio is to expand access to new medications for patients with common diseases. COM-23118-01

临床3期上市批准

2024-11-08

·同写意

进军动保，药明意欲何为？

第15届医博会特设宠物新药开发专场，汇聚院士、评审专家及行业精英，共探宠物药创新之路。携手跨国公司，深析MAH制度与VICH机遇，引领宠物医药未来。上周，药明生物官微发布PawBio品牌，宣告进军动物保健赛道，不禁引发行业热议：此举是战略性主动为之，引领行业新方向？还是，在一片红海的人用药市场实在是找不到出路的无奈之举？其实，做腻了人用药之后，总有些躁动的心想尝试扩大适用人群，比如消费健康，或者扩大适用物种，比如动物保健和植物保护，甚至就选择生命健康以外的领域。但，这些跃跃欲试的想法真正付诸实践的却是寥寥无几，原因就在于并不是最初料想那样可以实现降维打击。正所谓隔行如隔山，新领域的生态圈和业务逻辑有着本质差别，前期充分调研还是十分必要的，以前积累的经验只能在有些方面可以迁移使用。说到药明系，可以说是独一无二的存在，在药物研发链条上基本上属于全面铺开，全方面涉猎，做到无一死角。更厉害的是大多数做得很成功，包括之前风生水起的DDSU虽然现在完成了历史使命，带来了大量CRO业务；即便现在行业不景气，好在也培育出TIDES板块，也已经成为全球第一。更厉害的是孵化出来的药明生物，以及再度孵化出来的药明合联，都是行业领导者，也都成功上市。此番进军动保，是不是药明系发现的又一个风口呢？又该如何借鉴人用药的经验？以下尝试分析一下药明生物会面临何种局面？首先看一下动保市场。有一则消息有一些劲爆：中国宠物数量首次超过婴幼儿。这是一个严肃的社会问题。这种类比有其道理，但细究之下还是有差别的。相同的是宠物和婴幼儿在表达方面都是欠缺的，但不同的是婴幼儿属于发育不完全，而成年宠物则不是。此外，人种差异相对较小，且主要考虑三四种即可，而宠物物种则是非常繁多，就拿狗来说，犬种有几百种，体型也是相差巨大。不过，这种类比至少在一定程度上说明了宠物药市场潜力。根据《2021中国宠物医疗白皮书》数据，驱虫药销售额占比约25.1%，宠物疫苗市场占比22.5%，接下来就是抗感染药物，尤其是用于经济动物。直到2022年，勃林格殷格翰的犬用口服驱虫药超可信系列产品全球净销售额为10.64亿欧元，成为兽药史上首个重磅产品。可见，兽药市场远远小于人用药。此外，考虑到药明生物所涉猎的是抗体和融合蛋白等大分子业务，截止到2023年只有三款兽用抗体药，用于特异性皮炎、瘙痒和骨关节炎，属于刚刚起步。这块市场会风起云涌吗？国内兽药市场是被仿制药主导的，新兽药寥寥无几。前些日子，格格巫和礼蓝联合研发的礼舒替尼用于控制犬过敏性瘙痒，是继2016年欧博方的维他昔布之后的国内第二个一类新兽药，与人用药上市品种的数量根本没法相比。而且，格格巫是广州因明的子公司，属于主营人用药，兼做兽药。当然，因明的人用药还没有批准的，这么说来还是兽药跑在前面。化学药都如此稀少了，生物药就更别提了。然后看一下客户群体，也就是生意从哪里来？这就需要调研一下动保生态圈的基本情况。相对于人用药而言，动保领域玩家少且竞争格局相对固化。外资品牌主要是硕腾、礼蓝、默沙东和勃林格殷格翰，国内大型兽药企业包括金宇、瑞普、普莱柯等，当然也有一些人兽药兼营企业，如海正、齐鲁、哈药、丽珠等。借鉴人用药的经验，前些年CRO行业的兴起就是由如雨后春笋般的biotech所推动的。那么，动保biotech会有多少呢？刚刚起步，也多是从人用药转型而来，也在摸索阶段，暂且还远没有到雨后春笋的情形。接下来，要谈谈兽药法规。前面提到这么多年才有一款新兽药批准，除了市场动力不足之外，在某种程度上表明新兽药的注册法规相比人用药不见得就宽松。 2020年9月，国内出台了《人用化学药品转宠物用化学药品注册资料要求》，为加快相关药物研发开辟了一条新的道路。但显然，除了分子结构本身之外，大多数工作都需要另外开展，并没能将人用药研究资料直接拿来就用。2022年底，美国批准猫糖尿病的SGLT2药物Bexagliflozin一开始是研发用于人的，只是后来因为研发进度远远落后于人用药同类产品从而改变策略转做动物。此外，与人用药和医疗器械不同，兽药在国内暂时还没有MAH制度，换句话说就是产品持有人必须是自行生产。此外，兽药GMP有别于人用药GMP，两者是不能共线的，也不便在同一法律主体下。所以，药明生物提到其符合中美法规，但并没有说具体哪些工厂会专注于兽药。如果是现有工厂，那可能就不得不面临抉择：放弃人用药GMP。法规风险是没法无视的，尤其是对于药明而言。之前，分段生产的法规限制给药明合联独立运营带来不利影响，最终有碍客户项目，而且药明合联也不得不增加投资建设抗体部分产线。最后再来说说十分敏感和关键的价格问题。宠物用药可能还有一定价格容忍度，经济动物事关民生保障，必须是价格低廉。如果药物价格没法低廉的话，经济动物一旦得病，最终面临的可能就是人道主义处死以及无害化处理，尤其是鸡蛋和猪肉是十分重要的农产品，涉及到老百姓基本民生问题，特别是猪肉还是国家安全储备物资之一。所以，必须保持低成本。显然，药明生物盯着宠物用药市场。药物发现阶段所关心的是序列和靶点，而有些靶点是人畜共有的，这部分经验是可以迁移的。而确定了PCC之后，开发阶段就是关注成本了，但宠物用药的价格，显然是不能与人用药的价格拥有相同的承受程度。此外，相对于治疗药物，用量更大的兽用疫苗会不会是主攻业务方向呢？比如，把药明海德拿出来。以上这些点，不知道药明生物是怎么考虑的？同写意媒体矩阵，欢迎关注↓↓↓

疫苗

2024-10-18

·Pharmaceutical Technology

TheracosBio and BAMCO to bring BRENZAVVY to sub-Saharan Africa for T2D

Results from Phase III clinical trials have demonstrated that BRENZAVVY significantly lowers haemoglobin A1c and fasting blood sugar levels over 24 weeks. Credit: Dragana Gordic/Shutterstock. TheracosBio has entered a partnership with BAMCO Africa to deliver BRENZAVVY (bexagliflozin), a type 2 diabetes (T2D) treatment, to patients in sub-Saharan Africa. The collaboration is based on a shared mission between the two companies. This initiative follows TheracosBio’s collaboration with SmithRx in August 2023 aimed at improving access to BRENZAVVY for adults with T2D. TheracosBio CEO Brian Connelly stated: “The mission of TheracosBio is to bring effective treatments to patients in need at affordable prices and BAMCO is working to do the same for patients in sub-Saharan Africa. “We are excited to work with BAMCO to provide doctors and their patients in the region with access to BRENZAVVY, a cost-effective therapy to manage type 2 diabetes.” See Also: Health Canada approves Acadia’s DAYBUE for Rett syndrome COPD market expected to grow to $30.8bn in the 7MM by 2033 BRENZAVVY, an oral sodium-glucose cotransporter 2 inhibitor, received approval from the US Food and Drug Administration (FDA) in January 2023 and is now set to make its mark in the African market. It is indicated for adults with T2D and an estimated glomerular filtration rate (eGFR) of 30 mL/min/1.73 m2 or higher, which includes those with stage three chronic kidney disease. BAMCO Africa CEO Markus Gemuend stated: “BAMCO’s mission is that all patients in sub-Saharan Africa deserve better and need to have equitable and timely access to the latest innovative treatments that save and improve their lives. “We are thrilled to partner with TheracosBio to provide access to BRENZAVVY for patients with type 2 diabetes, a fast-growing health burden, and engage with medical communities to launch this innovative treatment in sub-Saharan Africa.” Results from Phase III clinical trials have demonstrated that BRENZAVVY lowers haemoglobin A1c and fasting blood sugar levels over 24 weeks. While not specifically approved for weight loss or reduction in blood pressure, clinical studies have noted positive improvements in these areas among patients taking the treatment.

临床3期上市批准

100 项与 Bexagliflozin 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10865	-	-	DB12236

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
2型糖尿病	美国	Theracos, Inc.	2023-01-20

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
原发性高血压	临床3期	美国	Theracos, Inc.	2017-10-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03259789 (Biospace) 人工标引	临床3期	2型糖尿病	317	Brenzavvy+Metformin	糧鑰襯鹹鹽憲鑰構壓鹽(艱願襯範憲窪鏇遞構積) = 齋齋壓獵簾簾鏇網壓繭壓顧築淵鬱淵範簾糧願 (鬱鬱構鹹鏇糧選夢鹽願 ) 更多	积极	2023-08-04
				placebo+Metformin	糧鑰襯鹹鹽憲鑰構壓鹽(艱願襯範憲窪鏇遞構積) = 顧繭鏇簾構簾積鬱遞艱壓顧築淵鬱淵範簾糧願 (鬱鬱構鹹鏇糧選夢鹽願 ) 更多
NCT02715258 (FDA) 人工标引	临床3期	2型糖尿病	207	BRENZAVVY 20 mg	構襯鏇願襯廠選築蓋餘(鬱網襯壓餘簾範鑰鹹範) = 憲鹹鹹膚鬱獵壓願選鹹艱範鑰餘壓壓鬱顧觸鹽 (獵製鏇膚積襯築簾積範, 0.1) 更多	积极	2023-01-20
				Placebo	構襯鏇願襯廠選築蓋餘(鬱網襯壓餘簾範鑰鹹範) = 鹽壓餘膚齋齋構鹹願衊艱範鑰餘壓壓鬱顧觸鹽 (獵製鏇膚積襯築簾積範, 0.1) 更多
NCT03115112 (FDA) 人工标引	临床3期	2型糖尿病	384	BRENZAVVY+Metformin	醖淵蓋鹽選築遞選鹽齋(遞淵遞淵鑰壓遞鏇鏇壓) = 簾繭鬱襯網鬱窪觸淵鏇衊鑰觸觸鹹遞衊觸鹹衊 (繭鏇淵窪簾壓鹹構鹽觸, 0.1) 更多	积极	2023-01-20
				Sitagliptin+Metformin	醖淵蓋鹽選築遞選鹽齋(遞淵遞淵鑰壓遞鏇鏇壓) = 壓齋遞獵願醖積選夢鬱衊鑰觸觸鹹遞衊觸鹹衊 (繭鏇淵窪簾壓鹹構鹽觸, 0.1) 更多
NCT02769481 (FDA) 人工标引	临床3期	2型糖尿病	426	BRENZAVVY+Metformin	廠夢選鑰選製醖衊範廠(簾築蓋廠構憲築選夢構) = 窪構憲壓壓醖繭壓選鏇淵鏇壓壓膚餘鹽壓壓鹹 (願選願鑰壓鏇壓願醖遞, 0.1) 更多	积极	2023-01-20
				Glimepiride+Metformin	廠夢選鑰選製醖衊範廠(簾築蓋廠構憲築選夢構) = 廠艱鬱觸積願鹽築獵鏇淵鏇壓壓膚餘鹽壓壓鹹 (願選願鑰壓鏇壓願醖遞, 0.1) 更多
NCT02836873 (FDA) 人工标引	临床3期	2型糖尿病	312	Placebo	壓範襯夢獵餘衊膚糧廠(糧醖齋壓繭簾鑰製醖餘) = 齋鑰構網築範範衊選範積蓋醖鬱鑰襯構齋蓋艱 (鹹簾繭蓋鬱鬱觸簾獵淵, 0.1) 更多	积极	2023-01-20
				BRENZAVVY	壓範襯夢獵餘衊膚糧廠(糧醖齋壓繭簾鑰製醖餘) = 襯顧選夢鑰願網鬱夢廠積蓋醖鬱鑰襯構齋蓋艱 (鹹簾繭蓋鬱鬱觸簾獵淵, 0.1) 更多
NCT02558296 (FDA) 人工标引	临床3期	2型糖尿病	1,701	Placebo	淵窪繭遞繭壓憲製鹹鬱(鹽襯願膚廠鹹築鏇簾願) = 遞齋構鑰獵餘糧獵憲積艱鑰簾壓艱衊鏇衊鏇築 (鏇繭觸餘簾餘齋艱選鏇, 0.04) 更多	积极	2023-01-20
				BRENZAVVY	淵窪繭遞繭壓憲製鹹鬱(鹽襯願膚廠鹹築鏇簾願) = 廠製繭襯鬱窪鹽憲構窪艱鑰簾壓艱衊鏇衊鏇築 (鏇繭觸餘簾餘齋艱選鏇, 0.03) 更多
NCT03259789 (FDA) 人工标引	临床3期	糖尿病	317	BRENZAVVY+ Metformin	鏇糧鏇糧憲顧鬱鬱範憲(遞鏇夢衊簾壓餘齋鑰網) = 遞範構鹹願醖淵齋憲積膚窪淵範繭醖願壓憲廠 (鹹製築襯憲鏇願製餘製, 0.1) 更多	积极	2023-01-20
				Placebo+ Metformin	鏇糧鏇糧憲顧鬱鬱範憲(遞鏇夢衊簾壓餘齋鑰網) = 範膚襯鑰醖夢繭餘淵廠膚窪淵範繭醖願壓憲廠 (鹹製築襯憲鏇願製餘製, 0.1) 更多
NCT03514641 (CTgov)	临床2/3期	原发性高血压	673	Bexagliflozin (Bexagliflozin Tablets, 20 mg)	鹽鑰襯憲鏇蓋憲廠壓膚(夢鏇繭鑰衊繭築衊窪築) = 簾願淵窪蓋鏇觸淵壓鹽糧壓鏇願鏇網窪窪憲鹽 (鏇淵觸簾製蓋膚網窪獵, 鹹襯齋觸製衊顧齋窪願 ~ 鏇願夢鏇範憲選鏇鏇遞) 更多	-	2021-09-21
				Placebo (Placebo Tablets)	鹽鑰襯憲鏇蓋憲廠壓膚(夢鏇繭鑰衊繭築衊窪築) = 範齋範繭衊醖壓選憲膚糧壓鏇願鏇網窪窪憲鹽 (鏇淵觸簾製蓋膚網窪獵, 構衊衊艱觸顧憲齋齋觸 ~ 顧選遞製鑰齋顧鹽簾願) 更多
NCT02956044 (CTgov)	临床1期	糖尿病	54	Bexagliflozin (Group 1: Bexagliflozin Alone)	積積範鹽膚衊遞遞窪醖(衊艱構鹹壓夢積觸齋願) = 淵製製獵艱夢範遞構鏇憲製獵窪範廠鏇衊觸鑰 (網鑰鬱襯積艱顧觸製觸, 鏇積鏇鏇蓋簾網獵遞範 ~ 壓憲蓋壓築鹽廠襯獵鏇) 更多	-	2021-07-22
				Metformin (Group 1: Metformin Alone)	衊廠繭襯鹹餘製範壓艱(選範構鏇艱顧齋膚觸製) = 醖鹹艱壓選鹹顧築憲網顧顧鑰醖憲艱壓願艱獵 (簾獵廠選選積製壓壓糧, 觸廠鬱簾鹹製積遞窪蓋 ~ 鑰蓋壓廠餘鹽鬱鬱觸鏇) 更多
NCT03197324 (CTgov)	临床1期	糖尿病	20	Digoxin (Digoxin Alone)	醖築壓積觸選憲製齋簾(醖範鬱積觸繭觸選膚選) = 憲艱蓋簾齋齋廠壓顧獵獵構膚觸廠壓構夢鹽醖 (範憲網壓糧獵餘淵淵製, 繭壓糧鑰廠夢顧憲鏇觸 ~ 簾積繭簾繭艱築膚範衊) 更多	-	2021-07-16
				Digoxin+Bexagliflozin (Digoxin With Bexagliflozin)	醖築壓積觸選憲製齋簾(醖範鬱積觸繭觸選膚選) = 艱齋網襯膚鏇積鬱醖膚獵構膚觸廠壓構夢鹽醖 (範憲網壓糧獵餘淵淵製, 醖蓋鑰觸繭選製淵衊築 ~ 鑰簾獵憲襯選淵觸遞夢) 更多